Digital self-management tools and coaches should be considered as appropriate support options
Emerging Manufacturers and Novel GLP-1 Mechanisms Viking Therapeutics is developing VK2735, a dual GIP/GLP-1 receptor agonist currently in late-stage trials, with data suggesting weight loss comparable to tirzepatide
Jeg er jo lge for fanden
GLP-1 (Glucagon-like peptide-1) medications have gained significant attention in recent years due to their ability to aid in weight loss and improve metabolic health
Other common side effects you may experience on Zepbound are: low blood sugar (hypoglycemia) - especially when used with other diabetic medications, so your dose may need to be lowered nausea, sickness * diarrhoea * constipation headaches allergic reaction indigestion, bloating, gas, burping, heartburn, acid reflux fatigue fast pulse increased levels of pancreatic enzymes in the blood * These usually happen when you first start using Zepbound but typically pass after a couple of weeks
hyperthyroidism rates are 1.7%, 0.6%, 3.2%, and 8.0%, respectively